☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-bbb
Share this
PS Admin
Jun 20, 2024
Clinical Trials
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-bbb
Click here
to read the full press release
Comments
Fill this Details
×
Name
Email
Company Name
Thank you for download PDF
Submit
Related News/Articles
Regulatory
Tubulis Reports the US FDA’s Fast Track Designation of TUB-040 to Treat Ovarian Cancer
June 28, 2024
Clinical Trials
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-aa
June 20, 2024
PanTher Therapeutics Reports the US FDA’s IND Clearance of PTM-101 to Treat Pancreatic Cancer
August 14, 2024
Weekly Snapshot
PharmaShots Weekly Snapshots (July 29 – August 02, 2024)
August 2, 2024
Celltrion’s Steqeyma (Biosimilar, Stelara) Receives the Health Canada’s Approval to Treat Various Chronic Inflammatory Conditions
August 2, 2024
Pharma
BostonGene and Takeda Collaborate to Investigate Immunotherapies through Molecular Profiling
August 2, 2024
BostonGene and Takeda Collaborate to Investigate Immunotherapies through Molecular Profiling
August 2, 2024
Xbrane Biopharma Reclaims Rights of BIIB801 (Biosimilar, Cimzia) from Biogen
August 1, 2024
Dr. Reddy’s Ituxredi (Biosimilar, MabThera) Receives the CHMP’s Positive Opinion
August 1, 2024
Valneva and LimmaTech Biologics Join Forces to Develop Shigella4V Against Shigellosis
August 1, 2024
Liked our insights or summarized news?
Subscribe to our Daily/Weekly newsletter
×
First Name
Last Name
Daily Newsletter
Weekly Newsletter
I agree to the privacy policy and terms.(
Link
)
Stay Connected
LinkedIn
Twitter
Facebook
instagram
Youtube
Join the PharmaShots family of 12000+ subscribers
Newsletter
Subscribe Now
I accept the
Terms and Conditions
X
Liked our insights or summarized news?
Subscribe to our Daily/Weekly newsletter
Subscribe
